title: Intramuscular interferon beta-1a and evolving treatment options and outcomes measurement for MS: considerations for managed care.
authors: Infusion Communications, Inc 7 Island Dock Rd., Haddam, CT 06438, USA. chris.barnes@infusioncomms.com
authors: Christopher J
authors: CJ
authors: Barnes
authors: Christina
authors: C
authors: Caon
authors: John F
authors: JF
authors: Foley
authors: Mark
authors: M
authors: Friedman
authors: Joseph
authors: J
authors: Menzin
authors: Kavita V
authors: KV
authors: Nair
authors: Christine
authors: C
authors: Nichols
authors: Eleanor L
authors: EL
authors: Olvey
authors: Gary M
authors: GM
authors: Owens
authors: Michael W
authors: MW
authors: Pill
authors: Grant H
authors: GH
authors: Skrepnek
authors: Leigh Ann
authors: LA
authors: White
authors: Kristine
authors: K
authors: Zerkowski
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007273:Injections, Intramuscular; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000008:administration & dosage* / Q000627:therapeutic use*; D008329:Managed Care Programs; D009103:Multiple Sclerosis / Q000188:drug therapy*; D017063:Outcome Assessment, Health Care
chemical_list: D000276:Adjuvants, Immunologic; D016899:Interferon-beta; D000068556:Interferon beta-1a